Ambrx Biopharma, Inc. (NASDAQ: AMAM) opened trading Thursday down, on the announcement of its addition to the NASDAQ Biotechnology Index effective prior to the market open on Monday, December 18.
“2023 has been a transformational year for Ambrx, .
Ambrx Biopharma Inc. (NYSE:AMAM – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target […]
Ambrx Biopharma Inc. (NYSE:AMAM – Get Free Report) CEO Daniel J. O’connor sold 50,012 shares of the company’s stock in a transaction dated Friday, October 27th. The stock was sold at an average price of $9.82, for a total value of $491,117.84. Following the completion of the sale, the chief executive officer now directly owns […]
Researcher explores drug repurposing for treatment of rare diseases medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Ambrx (AMAM) Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.